Dupilumab Provides Acceptable Safety and Sustained Efficacy for up to 4 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic Dermatitis.

ABSTRACT:

Background

Moderate-to-severe atopic dermatitis (AD) often requires long-term management with systemic therapies.

Objective

Our objective was to report the safety and efficacy of dupilumab treatment up to 4 years in adults with moderate-to-severe AD and efficacy in a subgroup of patients who transitioned from dupilumab once-weekly (qw) to administration every other week (q2w).

Methods

This interim analysis of the open-label extension study (NCT01949311) evaluated dupilumab 300 mg qw or q2w in adults previously enrolled in dupilumab trials for moderate-to-severe AD. Patients switched from qw to q2w following protocol amendment. The primary outcome was safety; efficacy was also assessed.

Results

Of 2677 patients enrolled and treated, 352 (13.1%) completed week 20

SUBMITTER: Beck LA 

PROVIDER: S-EPMC9063621 | biostudies-literature | 2022 May

REPOSITORIES: biostudies-literature